Sign In / Register
What is Armored RNA Technology?
Armored RNA® and Armored DNA™ technologies stabilize and protect nucleic acids from nuclease degradation by packaging them in a protective protein coat. Armored reagents deliver several end-user benefits, including:
Optimized Workflow
Armored RNA, Armored RNA Quant and Armored DNA Quant controls can be added directly to human matrices as an exogenous internal control for extraction with most nucleic acid isolation methods and detection in molecular assays.
Flexibility
Nuclease-resistant protein coat can also be removed by heat lysis for direct detection as a positive run control. For Armored RNA Quant and Armored DNA Quant, analytical quantification is performed with a validated method referencing a NIST-traceable phosphate standard.
SARS-CoV-2
| Description | Part # | Configuration |
|---|---|---|
| Targets the Nucleocapsid 1 and Nucleocapsid 2 regions of the CDC recommended Diagnostic Panel (CDC-006-00019). | 52151 | 1x106 cp/mL 250μL |
| Target | Size | Sequence |
|---|---|---|
| N1N2 | 1105 |
GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC |
Download Armored RNA Quant® SARS-CoV-2 PDF
SARS-CoV-2 Panel
| Description | Part # | Configuration |
|---|---|---|
| Contains multiple regions of SARS-Cov-2 genome including nucleocapsid, envelope, RNA-dependent RNA polymerase, open reading frame 1, and human RNAse P as an internal control. | 52153 | 1x106 cp/mL 250μL |
| Target | Size | Sequence |
|---|---|---|
| N | 1105 |
GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC |
| E | 193 |
TGTGCGTACTGCTGCAATATTGTTAACGTGAGTCTTGTAAAACCTTCTTTTTACGTTTACTCTCGTGTTAAAAATCTGAATTCTTCTAGAGTTCCT |
| RdRp | 787 |
TGTAGAAAACCCTCACCTTATGGGTTGGGATTATCCTAAATGTGATAGAGCCATGCCTAACATGCTTAGAATTATGGCCTCACTTGTTCTTGC |
| ORF1 | 350 |
TGGTGCATCGTGTTGTCTGTACTGCCGTTGCCACATAGATCATCCAAATCCTAAAGGATTTTGTGACTTAAAAGGTAAGTATGTACAAATACCT |
| RNP | 119 |
GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATTCAA |
Download Armored RNA Quant® SARS-CoV-2 Panel PDF
SARS-CoV-2 Spike Variants
| Description | Part # | Configuration |
|---|---|---|
| Targets mutations in the SARS CoV-2 spike protein prevalent in the Alpha (B.1.1.7), Beta (B.1.351), Gamma (B.1.1.28), Delta (B.1.617.2), and Omicron (B.1.1.529) strains. |
52160/52154 |
1x106 cp/mL 250μL |
| Target | Size | Sequence |
|---|---|---|
| 1877 |
CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTAC |
| Target | Size | Sequence |
|---|---|---|
| N | 1877 |
CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTT |
Download Armored RNA Quant® SARS-CoV-2 Spike Variants PDF
Respiratory Triplex
| Description | Part # | Configuration |
|---|---|---|
| Contains regions of SARS-Cov-2, Influenza A (H1N1, H3N2, and H7N9), Influenza B, Respiratory Syncytial Virus A (RSVA), Respiratory Syncytial Virus B (RSVB), and RPP30 as an internal control. | 52108 | 1x108 cp/mL 250μL |
| Target | Size | Sequence |
|---|---|---|
| CoV-2 | 1001 |
GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAA |
| Flu | 1430 |
ACGCGTGATCAGCAGAAGCAGGGGTTTAATTCTCATGGAATGGCTAAAGACAAGACCAATCTTGTCACCTCTGACTAAGGGAATTTTAGGA |
| RSVA | 589 |
CCTGTGAATATGGGAGGTTTCATCAAATGTATCTCATTAAGCTTAGGTATGAGAATAATTCTGTTAGGACATACATTAGTAAATTGTTCTACTAC |
| RSVB | 383 |
TGATGATTTTTGATCAGTGATCAACTCACTCAGCAATCAACAACATCAATAAAACAGACACCAATCCATTGAATCAATTGCCAGACTGAAAAAA |
| RNP | 119 |
GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATT |
Download Armored RNA Quant® Respiratory Triplex Control PDF
Armored RNA Quant® EPA 1615 Controls
| Description | Part # | Configuration |
|---|---|---|
| Contains sequences detected by the Enterovirus, Norwalk GI, and Norwalk GII virus assays described in EPA Method 1615 - Measurement of Enterovirus and Norovirus occurrence in water by culture and RT-qPCR. | 52000 | 1x1012 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| Nor-1 | 96 | G CCATGTTCCGCTGGATGCGCTTCCATGACCTCGGATTGTGGACAGGAGATCGCGATCTTCTGCCCGAATTCGTAAATGATGATGGCGTCTAAGG |
| Nor-2 | 91 | A ATGTTCAGATGGATGAGATTCTCAGATCTGAGCACGTGGGAGGGCGATCGCAATCTGGCTCCCAGCTTTGTGAATGAAGATGGCGTCGA |
| EV | 196 | C CTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGCAAGTCCGTGGCGGAA CCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCGAATTGGATTGGCCATC CGGT |
Download Armored RNA Quant® EPA 1615 Controls PDF
Enterovirus
| Description | Part # | Configuration |
|---|---|---|
| Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990). | 42102 | 5x105 cp/mL 5x100μL |
| Target | Size | Sequence |
|---|---|---|
| 263 | TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGC AAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCG AATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG |
Download Enterovirus PDF
Pentavalent Arbovirus Control
(CHIKV,DENV,WNV,YFV,ZIKV)
| Description | Part # | Configuration |
|---|---|---|
| Targets regions of the Chikungunya, Dengue, West Nile, Yellow Fever, and Zika viruses. | 49659 | 1x108 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| 2200 | CCGACTCAACCATCCTGGATTTGCCAGCAAGGAGGATGATGTCGGACAGGAAGTACCACTGCGTCTGCCTTCATCTGCACCCAAGTGTACCATT GCGGTGTACACTGCCTGTGACCGCTTCATTACGAAGGCAAAATGCGCTTGAGCATATGGTTACGCAGATAGTTACGAGTCATCTGCGTATTGGG ACGCATTGAAACCACCATGTGTCACCAGCATTTGTACTGGCAGCAGCCACGTTAACGTCACACAGATGAGTTGAATTTGCTGCCAGCCCTATTTC GAAAAGGAACCGGAGGAAACCCTACGCATGCTTGATTAACGTCATGAGACCTGGGTACTATCTTAAGCTCCGCGTCCTTTACCAAGTTCCAATGT CTTCAGCCTGGACACCTTTTTAGGAAGACCAGGACAATTTGGTTGTCACATACCACCCTCGTTGGGACTGGTTGTTGCTGTTGCCGCTTAGGTAT ATGTGTCCCCTAAGAGACATTCAGATCTCTGATGAACAACCAACGTTATATGCTGAAACGCGCGAGTTGTTGGCGAAGAGATTCTCAAATTCAAA AGGAAGTCGTGCAATATTCATGTGGCTGGGAGCACGCTTGTTTAGTAGAGAGAATTCACTCAGTTGACTAGTGGTTAGAGGAGACCCCTCCCTT AAGGACTAGAGGTTAGAGGAGACCCCCTTACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACA GAACGCCAGAAAATGGAATGGTTTAGTAGTTCGCCTGTGTGAGCTGACAAACTTAGTAGTGTTTGTGAGGATTTTTGCGAGCTGTTTCTTAGCAC GAAGATCTCGATGTCTAAGAAACCAGGAGGGCTTGGCTGTCAATATGCTAAAACGCTTCTACCGTCAGCGATCTCTTCATGGGAGAAGCTCACTT CAAACGTGCTGACCCAGTTCCTTTTCAGTTGGGCCTTCTGGTCGTGTTCTTCCACCCAGGAGGTCCTTCGCAAGAGGTGGACAGCCAAGATCAGC ATGCCAGCTTTTGGGGGCATTACTTACACTGTTCGCTGTCCCTGTGAATTGTTTGGTCCATCCATGCAGGAGGAGAGTTGTCTGGAACCGTGTTTG GTTCCACCGGAAGTTGAGTAGACGGTGCTGCCTGCGACTCAACCCCAGGAGGACTGGGTGAACAAATTCCATGTAAGCCCTCAGAACCGTCTCG GAAGGTTGCTAATTGAGGTGCATTGGTCTGCAAATCGAGTTGCTAGGCAATAAACACTTATCGTTCGTTGAGCGATTAGCAGAGAACTGACTTTCT GGTCGTAAAGCTCAGGGATTACAACATGATGGGGAAAAGAGAGAATTTGGTACATGTGGCTGGGAGCTTCGCGGATGACACCGCTGGATGGGA CACGTGCACGGATGTGACAGACTGAAAATTCGATTGTGTTGTCCGGCCCATCGATGACAGGTTCGGCCTGGTTTGGTCATGATACTGCTGATTGC CCCGGCATATAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAG CAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGTTTGGCAAAGGGAGCCTGGTGTAAGTTTGCATGCTCCAAGAAAATTACCGGGAAG AGCATCCAGCCAGATATCTGGAGTACCGGATAATGCTGTCAACCACTGCAAGCGGAAGGTTATGGTGCTGCAGGGAGTGCACAATGCCCCCACT GTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCATCTGTGGCATGAACCCAATAGTCCTTTGCAGCTGGAGCGTGGTG GAGTGGTGCTCTATGGGATTCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTTGGAGAAAAAGATGGGACAGGTGTTACGCTC AGAGTCCTCTCCATGTTTGTGCCCATACACCAGTTGATGGAAACCCTGGAGCGACTTAAGTACACATACCAAAACAAAGTGGTTTCTTAGACCAGC TGAAATTCAAGACCAAAGGGGGAGCGGATCTCAATGTTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAACCCCCC CAGGAGAAGCTGGGAAATCAAGCTC |
Download the Pentavalent Arbovirus Control PDF
Zika Virus
| Description | Part # | Configuration |
|---|---|---|
| Targets regions of the Zika virus. | 49610 | 5x105 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| 2164 | GCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCA GCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATATTGTCTTGGAACATGGAGGTTGTGTCACCGTAATGGCACAGGA CAAACCGCATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGC CTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAG GGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCT GTCAGTTCACTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAG TGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCA AAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGA GAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGG AGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAAT GCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAA TGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAA TGACCACAAAGATCATCCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGT GGTGCTCTATGGGATCAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAA GAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACC ATAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGG CTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGA AACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCCACACAAGGGTCAGCGTCCTCTCTAATA AACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAA AGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCCAAGGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAG AGAACTCAGGAGGTGGTGTTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATG CAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGG CCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGACATTATT TCGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCAC |
Internal Process Control (Armored RNA Quant)
| Description | Part # | Configuration |
|---|---|---|
| Targets a non-specific, 1,000 nucleotides in vitro transcribed RNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process. | 49650 | 1x106 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| 1000 | GTACTGACGTAAAGTCACTATTTTTCGTGCAACGTACGTCTCGATGTACAACTGCTCTATTACGGTTCATTTTTTTTGTAGGGTTACGCGGCCA GATGACTCCATCTTATCCCCTTGAAAACATTCTTATTTGTACGCCATAGTGGCATCGCGGTTGGATATCAATCGTATTGGACGCAAGCGCGCT CTACTCAGTTTATAAGACCGCCAACTATTTTCGCAAGATCAGTGTATTTACGCTGACTCCAGTGGTGAAACTCCTAAGATCTGTTTAGCTATTG CGCCGTGCGTTTATCAAATCGGGCTTCCCAACATTCATTCTTAGAAGGAAGCTCGATAGTTCAGAGCTGCGGAAGGCCCAATTTCATATTATA TGTATGAGCCTGTCAATACCTGCACCCACGAACACCACAGTGACTAGAGTATGAGAGGTCGACGATCTACGGATGGTGATGAGCACGGAGAT CTAAGCGTGGAAGTGGCTATATAGAGCAGATATATTATATGACGTACCAGAGGATCACCTACTAAAAGACTTTTCGAGAATCTACACCTACTAG CAAGGGTAGCCGATTAGTGGATCATCTAAGACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCA GCCTTTGCCGCGGCACATAGCGATATCCCGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGAC TAGCCAGGCGTTTCCCGCGTTTCTAGATATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTA ATCTTTAGGCTGCGGCCGCTTAGGTGGCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATG GATCTTTAATATAATCTAGGCAACAAGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCT |
Download the Internal Process Control PDF
RNase P
| Description | Part # | Configuration |
|---|---|---|
| Targets the human RNase P gene; often used as an internal control because abundant copies in the human genome make it readily detectable. | 52152 | 1x106 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| 144 | GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTT GTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT |
Mpox Nonvariola Orthopox Control
| Description | Part # | Configuration |
|---|---|---|
| A single, concatenated construct of both nonvariola Orthopox and Mpox-specific sequence blended with with RNAse P to allow for an all-in-one process control. The control is provided as two tubes of high and low concentration along with diluent for convenience. | 49670 | 500μL |
| Target | Size | Sequence |
|---|---|---|
| NVO/MPX | 300 | ATAATAAACGGAAGAGATATAGCACCACATGCACCATCCAATGGAAAATGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTAT CGTGTCCTCCGGGAACTTACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACGCCTAAAACAGGCTACCAGTTCAACTGAAA AGGCCATCTATGATTCCATGCAATATACGTACAAGATAGTAGCCAACTCAGTATATGGTCTGATGGGATTTAGAAATAGTGCTCTATACTCA TACGCTTCGGCTAAGAGTTGCACATC |
| RNP | 144 | GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACT TGTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT |
Download the Mpox/Nonvariola Orthopox Control PDF
Internal Process Control (Armored DNA Quant)
| Description | Part # | Configuration |
|---|---|---|
| Targets a non-specific, 495 base pair in vitro transcribed DNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process. | 52003 | 1x108 cp/mL 500μL |
| Target | Size | Sequence |
|---|---|---|
| 495 | GACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCAGCCTTTGCCGCGGCACATAGCGATATCC CGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGACTAGCCAGGCGTTTCCCGCGTTTCTAGA TATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTAATCTTTAGGCTGCGGCCGCTTAGGTG GCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATGGATCTTTAATATAATCTAGGCAACA AGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCTAAACATGAGGATTACCCATGTAAGCTTATTCCCTTTAGTGAGGGTTAATTTTAGCTTGGC ACTGGCCGTCGTTTTACAACGTCG |
Hepatitis G Virus
| Description | Part # | Configuration |
|---|---|---|
| Contains sequences amplified by primer binding regions for Hepatitis G Virus (Schlueter, 1996); the PCR product generated is 185 nucleotides. | 42024 | 250μL |
| Target | Size | Sequence |
|---|---|---|
| 263 | CCGGCACTGGGTGCAAGCCCCAGAAACCGACGCCTATTTTAAACAGACGTTATGAACCGGCGCTGACTCGGCGACCGGCCAAAAGGTGGTGG ATGGGTGATGCCAGGGTTGGTAGGTCGTAAATCCCGGTCATCTTGGTAGCCACTATAGGTGGGTCTTAAGGGTTAGTCAAGGTCCCTCTGGCG CTTGTGGCGAGAAGCGCACGGTCCACAGGTGTTGGCCCTACCGGTGTGAATAAGGGCCCGACGTCAGGCTCGTCGTTAAACCGAGCCCATTA CCCACCTGGGCAAACGACGCCCACGTACGGTCCACGTCGCCCTTCAATGTCTCTCTTGACCAATAGGCTTAGCCGGCGAGTTGACAAGGACCA |
Download the Hepatitis G Virus PDF
Enterovirus
| Description | Part # | Configuration |
|---|---|---|
| Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990). | 42050 | 250μL |
| Target | Size | Sequence |
|---|---|---|
| 263 | TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCG CAAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAA GCGAATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG |
Download the Enterovirus PDF
Astrovirus
| Description | Part # | Configuration |
|---|---|---|
| Astrovirus | 52214 |
Bacteriophage MS2
| Description | Part # | Configuration |
|---|---|---|
| Bacteriophage MS2 | 52223 |
Beta-Actin (ACTB)
| Description | Part # | Configuration |
|---|---|---|
| Beta-Actin (ACTB) | 52225 |
Ebolavirus
| Description | Part # | Configuration |
|---|---|---|
| Ebolavirus | 52217 |
Glucuronidase Beta (GUSB)
| Description | Part # | Configuration |
|---|---|---|
| Glucuronidase Beta (GUSB) | 52224 |
Hepatitis C Virus (GT 2b)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 2b) | 42101 |
Download the Hepatitis C Virus (GT 2b) PDF
Hepatitis D Virus
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis D Virus | 52212 |
HIV (Subtype B)
| Description | Part # | Configuration |
|---|---|---|
| HIV (Subtype B) | 42103 |
Human Papillomavirus 16
| Description | Part # | Configuration |
|---|---|---|
| Human Papillomavirus 16 | 52219 |
Human Papillomavirus 18
| Description | Part # | Configuration |
|---|---|---|
| Human Papillomavirus 18 | 52220 |
Norovirus GI.1
| Description | Part # | Configuration |
|---|---|---|
| Norovirus GI.1 | 52215 |
Norovirus GII.4
| Description | Part # | Configuration |
|---|---|---|
| Norovirus GII.4 | 52216 |
Sapovirus I
| Description | Part # | Configuration |
|---|---|---|
| Sapovirus I | 52213 |
Sapovirus I, II, IV
| Description | Part # | Configuration |
|---|---|---|
| Sapovirus I, II, IV | 52221 |
Sapovirus V
| Description | Part # | Configuration |
|---|---|---|
| Sapovirus V | 52222 |
Sudan Ebolavirus
| Description | Part # | Configuration |
|---|---|---|
| Sudan Ebolavirus | 52218 |
Dengue Virus (Type I)
| Description | Part # | Configuration |
|---|---|---|
| Dengue Virus (Type I) | 42044 |
Hepatitis C Virus (GT 1a)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 1a) | 42004 |
Hepatitis C Virus (GT 1b)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 1b) | 42006 |
Hepatitis C Virus (GT 2a/c)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 2a/c) | 42008 |
Hepatitis C Virus (GT 2b)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 2b) | 42010 |
Hepatitis C Virus (GT 3a)
| Description | Part # | Configuration |
|---|---|---|
| Hepatitis C Virus (GT 3a) | 42012 |
HIV (Subtype B)
| Description | Part # | Configuration |
|---|---|---|
| HIV (Subtype B) | 42000 |
Norovirus GI
| Description | Part # | Configuration |
|---|---|---|
| Norovirus GI | 42030 |
Norovirus GII
| Description | Part # | Configuration |
|---|---|---|
| Norovirus GII | 42032 |
SARS (BNI-1)
| Description | Part # | Configuration |
|---|---|---|
| SARS (BNI-1) | 42090 |
SARS (CoV-NC)
| Description | Part # | Configuration |
|---|---|---|
| SARS (CoV-NC) | 42091 |
West Nile Virus (Cap)
| Description | Part # | Configuration |
|---|---|---|
| West Nile Virus (Cap) | 42042 |
West Nile Virus (HNY1999)
| Description | Part # | Configuration |
|---|---|---|
| West Nile Virus (HNY1999) | 42040 |
West Nile Virus (NEN)
| Description | Part # | Configuration |
|---|---|---|
| West Nile Virus (NEN) | 42041 |
RNARetain Buffer
| Description | Part # | Configuration |
|---|---|---|
| Intended for the collection, storage, and transportation of fresh tissue specimens for subsequent RNA isolation and further molecular testing. Eliminates the need to immediately process specimens, enabling RNA extraction and molecular testing at a later time and/or transport to a different location. | 49536 | Volume 2L† |
†Variable concentrations, volumes and vial quantities available upon request
TSMIII Buffer
| Description | Part # | Configuration |
|---|---|---|
| A buffered solution ideally suited for the dilution of Armored products. The additives provide stability to the protein-coated nucleic acid through multiple freeze-thaws when stored properly, allowing for more flexible and scalable testing processes. | 49600 | Volume 50mL |
